Professor John Kane, principal investigator and lead author of the PRELAPSE study1,2, examines the results of the study and shares his expertise and insights on the challenges of non-adherence and its impact on recovery, as well as advice on utilising LAIs in practice, including when to initiate and how to increase acceptance.
Abilify Maintena PBS Information: Authority required (STREAMLINED). Code: 4246 for schizophrenia.
This product is not listed on the PBS for the treatment of bipolar 1 disorder.
Please review Approved Product Information before prescribing.
Product Information is available by calling Lundbeck on 1300 721 277 or by clicking:
Abilify Maintena is a registered trademark of Otsuka Pharmaceutical Co., Ltd. Abilify Maintena is co-commercialised by Lundbeck Australia and Otsuka Australia Pharmaceutical Pty Limited.
